Narmeen Akhtar1,2, Linda Lee2,3. 1. Faculty of Applied Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada. 2. Department of Oncology, Niagara Health, St. Catharines, ON L2S 0A9, Canada. 3. Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada.
Abstract
PURPOSE: To describe how central venous access devices (CVADs) are utilized for ambulatory oncology patients and to evaluate the rate of complications. METHOD: Single institution retrospective study of oncology patients with CVADs who received systemic treatment at the Walker Family Cancer Centre (WFCC) between 1 January and 31 December 2018. RESULTS: A total of 480 CVADS were placed in 305 patients, of which 408 (85%) were peripherally inserted central catheters (PICCs) and 72 (15%) were implanted vascular access devices (PORTs). The incidence of early and late complications was 9% and 24%, respectively. For the entire cohort, the rate of venous thromboembolism (VTE) was 16%, of which 9% were CVAD-related thrombosis (CRTs) and 7% were distant VTE. The CRT rates were similar for PICCs and PORTs (9% vs. 7%). A total of 6% of CVADs were complicated by infection (i.e., localized infections and bacteremia), with a total infection rate of 0.43 and 0.26 per 1000 indwelling days for PICCs and PORTs, respectively. The incidence of central line associated bloodstream infections (CLABSI) was greater for PICCs than PORTs, at a rate of 0.22 compared with 0.08 per 1000 indwelling days, respectively. The premature catheter removal rate was 26% for PICCs and 18% for PORTs. PORTs required more additional hospital visits. CONCLUSIONS: PICCs were utilized more frequently than PORTs and had a higher rate of premature removal. The rates of VTE and CRT were similar for both CVAD types. PORTs had a lower rate of infection per 1000 indwelling days. However, the management of PORT related complications required more visits to the hospital and oncology clinic.
PURPOSE: To describe how central venous access devices (CVADs) are utilized for ambulatory oncology patients and to evaluate the rate of complications. METHOD: Single institution retrospective study of oncology patients with CVADs who received systemic treatment at the Walker Family Cancer Centre (WFCC) between 1 January and 31 December 2018. RESULTS: A total of 480 CVADS were placed in 305 patients, of which 408 (85%) were peripherally inserted central catheters (PICCs) and 72 (15%) were implanted vascular access devices (PORTs). The incidence of early and late complications was 9% and 24%, respectively. For the entire cohort, the rate of venous thromboembolism (VTE) was 16%, of which 9% were CVAD-related thrombosis (CRTs) and 7% were distant VTE. The CRT rates were similar for PICCs and PORTs (9% vs. 7%). A total of 6% of CVADs were complicated by infection (i.e., localized infections and bacteremia), with a total infection rate of 0.43 and 0.26 per 1000 indwelling days for PICCs and PORTs, respectively. The incidence of central line associated bloodstream infections (CLABSI) was greater for PICCs than PORTs, at a rate of 0.22 compared with 0.08 per 1000 indwelling days, respectively. The premature catheter removal rate was 26% for PICCs and 18% for PORTs. PORTs required more additional hospital visits. CONCLUSIONS: PICCs were utilized more frequently than PORTs and had a higher rate of premature removal. The rates of VTE and CRT were similar for both CVAD types. PORTs had a lower rate of infection per 1000 indwelling days. However, the management of PORT related complications required more visits to the hospital and oncology clinic.
Entities:
Keywords:
central venous access devices; complications; implanted vascular access device; infections; peripherally inserted central catheter; venous thromboembolism
Authors: Vineet Chopra; John C O'Horo; Mary A M Rogers; Dennis G Maki; Nasia Safdar Journal: Infect Control Hosp Epidemiol Date: 2013-07-26 Impact factor: 3.254
Authors: G S Patel; K Jain; R Kumar; A H Strickland; L Pellegrini; J Slavotinek; M Eaton; W McLeay; T Price; M Ly; S Ullah; B Koczwara; G Kichenadasse; C S Karapetis Journal: Support Care Cancer Date: 2013-09-05 Impact factor: 3.603
Authors: W Saber; T Moua; E C Williams; M Verso; G Agnelli; S Couban; A Young; M De Cicco; R Biffi; C J van Rooden; M V Huisman; D Fagnani; C Cimminiello; M Moia; M Magagnoli; S P Povoski; S F Malak; A Y Lee Journal: J Thromb Haemost Date: 2011-02 Impact factor: 5.824
Authors: N LeVasseur; C Stober; K Daigle; A Robinson; S McDiarmid; S Mazzarello; B Hutton; A Joy; D Fergusson; J Hilton; M McInnes; M Clemons Journal: Curr Oncol Date: 2018-08-14 Impact factor: 3.677
Authors: Charles A Schiffer; Pamela B Mangu; James C Wade; Dawn Camp-Sorrell; Diane G Cope; Bassel F El-Rayes; Mark Gorman; Jennifer Ligibel; Paul Mansfield; Mark Levine Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Terri Jabaley; Niya Xiong; Susanne Conley; Teresa Mazeika; Danielle Johnson; Brenda A Biggins; Nancy Hilton; Fangxin Hong Journal: Can Oncol Nurs J Date: 2022-04-01
Authors: Terri Jabaley; Niya Xiong; Susanne Conley; Teresa Mazeika; Danielle Johnson; Brenda A Biggins; Nancy Hilton; Fangxin Hong Journal: Can Oncol Nurs J Date: 2022-04-01